hansoh actively implements the internationalization strategy and has been committed itself to human being’s health with its professional expertise, through sales of internationally certified apis and finished-dose pharmaceutical products to the u.s. and other countries, and international multi-center clinical trials for innovative drugs.
market internationalization
multiple finished-dose pharmaceutical products and apis are sold to the global market.
r&d internationalization
global multi-center clinical trials are under way simultaneously in the u.s. and china for hs-10296, a category 1.1 innovative oncology drug, amid efforts for global expansion of innovative drugs.